×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Therapeutic: cbs-psp-daily-action-plan
therapeutic
30,834 words
KG: CBS-PSP-DAILY-ACTION-PLAN
Contents
cbs-psp-daily-action-plan
💊
Therapeutic Info
Name
CBS-PSP-DAILY-ACTION-PLAN
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (46)
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.65
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.62
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61
LRP1-Dependent Tau Uptake Disruption
Score: 0.60
Brain Insulin Resistance with Glucose Transporter Dysfunctio
Score: 0.60
← Prev
pg 3/3
Related Analyses (19)
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Show 14 more
Related Experiments (30)
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Autophagy receptor identification for stress granule elimina
exploratory · proposed · Score: 0.90
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
AMPK knockdown validation experiment
exploratory · proposed · Score: 0.88
iPSC-NPC transplantation in ICH animal model
validation · proposed · Score: 0.85
Autophagy receptor knockout effects on stress granule accumu
exploratory · proposed · Score: 0.85
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
Mouse Cdk5, p35, and p39 mutations in neuronal migration
validation · proposed · Score: 0.80
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Show 25 more
See Also (15)
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 4 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 4 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 4 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 4 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
Olfactory Mucosa, Blood and Urine for Identification of
clinical · Pages share 4 hypotheses
Swedish BioFINDER 2 Study: Biomarkers and Neurodegenera
clinical · Pages share 4 hypotheses
Beta-Propeller Protein-Associated Neurodegeneration (BP
disease · Pages share 4 hypotheses
China Neurodegeneration Epidemiology
disease · Pages share 4 hypotheses
DALY Methodology — Neurodegeneration
disease · Pages share 4 hypotheses
Disease Progression & Staging in Neurodegeneration
disease · Pages share 4 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.